186 related articles for article (PubMed ID: 24119559)
21. Orthopaedics: Structural support.
Berglund J
Nature; 2011 Dec; 480(7377):S56-7. PubMed ID: 22169807
[No Abstract] [Full Text] [Related]
22. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors.
Han L; Wen Y; Li R; Xu B; Ge Z; Wang X; Cheng T; Cui J; Li R
Bioorg Med Chem; 2017 Aug; 25(15):4031-4044. PubMed ID: 28634039
[TBL] [Abstract][Full Text] [Related]
24. Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
Ju D; Xie Y
Mol Med Rep; 2014 Nov; 10(5):2609-12. PubMed ID: 25174315
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonate anticancer activity in multiple myeloma.
Terpos E
Anticancer Agents Med Chem; 2012 Feb; 12(2):123-8. PubMed ID: 21864228
[TBL] [Abstract][Full Text] [Related]
26. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
[TBL] [Abstract][Full Text] [Related]
27. Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
Opoku-Ansah J; Ibarra-Rivera TR; Pirrung MC; Bachmann AS
Pharm Biol; 2012 Jan; 50(1):25-9. PubMed ID: 22196580
[TBL] [Abstract][Full Text] [Related]
28. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Piva R; Ruggeri B; Williams M; Costa G; Tamagno I; Ferrero D; Giai V; Coscia M; Peola S; Massaia M; Pezzoni G; Allievi C; Pescalli N; Cassin M; di Giovine S; Nicoli P; de Feudis P; Strepponi I; Roato I; Ferracini R; Bussolati B; Camussi G; Jones-Bolin S; Hunter K; Zhao H; Neri A; Palumbo A; Berkers C; Ovaa H; Bernareggi A; Inghirami G
Blood; 2008 Mar; 111(5):2765-75. PubMed ID: 18057228
[TBL] [Abstract][Full Text] [Related]
29. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonate therapy in the treatment of multiple myeloma.
Lawson MA; Ashcroft J; Croucher PI
Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
[TBL] [Abstract][Full Text] [Related]
31. Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.
Zangari M; Berno T; Yang Y; Zeng M; Xu H; Pappas L; Tricot G; Kamalakar A; Yoon D; Suva LJ
Bone; 2014 Apr; 61():39-43. PubMed ID: 24389365
[TBL] [Abstract][Full Text] [Related]
32. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
de Carvalho F; Costa ET; Camargo AA; Gregorio JC; Masotti C; Andrade VC; Strauss BE; Caballero OL; Atanackovic D; Colleoni GW
PLoS One; 2011; 6(11):e27707. PubMed ID: 22110734
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
34. Development of proteasome inhibitors as research tools and cancer drugs.
Goldberg AL
J Cell Biol; 2012 Nov; 199(4):583-8. PubMed ID: 23148232
[TBL] [Abstract][Full Text] [Related]
35. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
[TBL] [Abstract][Full Text] [Related]
36. Entinostat-Bortezomib Hybrids against Multiple Myeloma.
Ferro A; Graikioti D; Gezer E; Athanassopoulos CM; Cuendet M
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771118
[TBL] [Abstract][Full Text] [Related]
37. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
38. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
39. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.
Gu Y; Kaufman JL; Bernal L; Torre C; Matulis SM; Harvey RD; Chen J; Sun SY; Boise LH; Lonial S
Blood; 2014 May; 123(21):3269-76. PubMed ID: 24713927
[TBL] [Abstract][Full Text] [Related]
40. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
